VBI Vaccines' Pan-Coronavirus Vaccine Candidate Shows Promising Protection Against Major COVID Variants in Early Trial

VBI Vaccines' pan-coronavirus vaccine candidate showed broad protection against major COVID variants in Phase 1 trial
Vaccine induced strong neutralizing antibody responses against Wuhan, Delta, Beta, and Omicron variants
Protective antibody levels remained high through 6 months with minimal decline
Participants with low baseline antibodies saw the greatest boosting effects after vaccination
Data showed vaccine was well tolerated with no concerning safety signals

marketwatch.com

Relevant topic timeline:

9/6/2023

Moderna says updated COVID vaccine is effective against newer variant

Moderna's updated COVID-19 vaccine is likely to be effective against the highly-mutated BA.2.86 subvariant of the coronavirus, according to clinical trial data, providing reassurance for fall boosters and regulators.

9/8/2023

Early Data Shows Existing Antibodies Can Fight New BA.2.86 COVID Variant, But Updated Vaccines Coming Soon

Antibodies from prior infection or existing vaccines have been found to protect against the BA.2.86 variant of the coronavirus, according to the U.S. Centers for Disease Control and Prevention (CDC).

9/13/2023

Updated COVID Boosters With Omicron Target Now Available, But Demand Uncertain

Americans can now receive an updated COVID-19 vaccine to reduce the severity of symptoms, protect against current variants, and curb the risk of "long COVID."